Neurosteroids reshape postpartum depression care: brexanolone to zuranolone
This narrative review consolidates the pharmacology, trial evidence, and practical selection considerations for neurosteroid antidepressants in postpartum depression, directly relevant to pharmacists counseling perinatal patients.
📅 Journal publication: Sep 2026·Last updated: Oct 7, 2026
Brexanolone and zuranolone redefine postpartum depression treatment with rapid action.
Perinatal depression affects many women and current treatments have limitations. New neurosteroid-based therapies offer rapid and lasting benefits. Brexanolone and zuranolone, synthetic neurosteroid analogs, show efficacious and sustained relief in postpartum depression through a unique mechanism. Advances in neurosteroid therapeutics for postpartum depression could guide precision medicine strategies, enhancing individualized treatment approaches. Neurosteroids like brexanolone and zuranolone are innovative, effective options for postpartum depression.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Radonjić NV, Moon KC, Deligiannidis KM The neurosteroid paradigm in perinatal depression: From pathophysiology to precision therapeutics. Journal of neuroendocrinology. 2026;38(9):e70253. doi:10.1111/jne.70253
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.